INDV
Indivior Pharmaceuticals Inc
Drug Manufacturers - Specialty & Generic
Market Cap$5.07B
5Y Perf.+915.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
INDV vs AVPT
Revenue, margins, valuation, and 5-year total return — side by side.
AVPT
AvePoint, Inc.
Software - Infrastructure
Market Cap$2.22B
5Y Perf.+4.9%
INDV vs AVPT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | INDV | AVPT |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Software - Infrastructure |
| Market Cap | $5.07B | $2.22B |
| Revenue (TTM) | $1.29B | $419M |
| Net Income (TTM) | $251M | $35M |
| Gross Margin | 83.1% | 74.1% |
| Operating Margin | 33.3% | 7.9% |
| Forward P/E | 13.0x | 27.6x |
| Total Debt | $351M | $10M |
| Cash & Equiv. | $195M | $481M |
INDV vs AVPT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
INDV
AVPT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Indivior Pharmaceut… (INDV) | 100 | 1015.3 | +915.3% |
| AvePoint, Inc. (AVPT) | 100 | 104.9 | +4.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INDV vs AVPT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: INDV leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. AvePoint, Inc. is the stronger pick specifically for growth and revenue expansion. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
INDV
Indivior Pharmaceuticals Inc
The Income Pick
INDV carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 0.68
- 291.3% 10Y total return vs AVPT's 5.0%
- Lower volatility, beta 0.68, current ratio 0.71x
Best for: income & stability and long-term compounding
AVPT
AvePoint, Inc.
The Growth Play
AVPT is the clearest fit if your priority is growth exposure.
- Rev growth 26.9%, EPS growth 193.8%, 3Y rev CAGR 21.8%
- 26.9% revenue growth vs INDV's 4.3%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AVPT | 26.9% revenue growth vs INDV's 4.3% |
| Value | INDV | Lower P/E (13.0x vs 27.6x) |
| Quality / Margins | INDV | 19.4% margin vs AVPT's 8.3% |
| Stability / Safety | INDV | Beta 0.68 vs AVPT's 1.06 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | INDV | +247.1% vs AVPT's -39.5% |
| Efficiency (ROA) | INDV | 19.1% ROA vs AVPT's 4.9%, ROIC 342.7% vs 11.4% |
INDV vs AVPT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
INDV vs AVPT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLINDVLAGGINGAVPT
AVPTAvePoint, Inc.
1leads
INDVIndivior Pharmaceutic…
3leads
6 Total Categories
CATEGORYLEADERvs AVPTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
INDV4/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AVPT5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
INDV4/6
Risk & VolatilityBeta, volatility, and downside exposure
INDV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — INDV and AVPT each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
INDV is the larger business by revenue, generating $1.3B annually — 3.1x AVPT's $419M. INDV is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to AVPT's 8.3%. On growth, AVPT holds the edge at +28.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | INDVIndivior Pharmace… | AVPTAvePoint, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1.3B | $419M |
| EBITDAEarnings before interest/tax | $447M | $39M |
| Net IncomeAfter-tax profit | $251M | $35M |
| Free Cash FlowCash after capex | -$185M | $80M |
| Gross MarginGross profit ÷ Revenue | +83.1% | +74.1% |
| Operating MarginEBIT ÷ Revenue | +33.3% | +7.9% |
| Net MarginNet income ÷ Revenue | +19.4% | +8.3% |
| FCF MarginFCF ÷ Revenue | -14.3% | +19.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.2% | +28.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +81.6% | +173.5% |
Evenly matched — INDV and AVPT each lead in 3 of 6 comparable metrics.
Valuation Metrics
INDV leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
At 24.8x trailing earnings, INDV trades at a 64% valuation discount to AVPT's 68.5x P/E. On an enterprise value basis, INDV's 18.3x EV/EBITDA is more attractive than AVPT's 44.5x.
| Metric | INDVIndivior Pharmace… | AVPTAvePoint, Inc. |
|---|---|---|
| Market CapShares × price | $5.1B | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $5.2B | $1.7B |
| Trailing P/EPrice ÷ TTM EPS | 24.76x | 68.47x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.97x | 27.61x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 18.33x | 44.52x |
| Price / SalesMarket cap ÷ Revenue | 4.09x | 5.29x |
| Price / BookPrice ÷ Book value/share | — | 4.92x |
| Price / FCFMarket cap ÷ FCF | — | 27.19x |
INDV leads this category, winning 4 of 4 comparable metrics.
Profitability & Efficiency
AVPT leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), AVPT scores 6/9 vs INDV's 4/9, reflecting solid financial health.
| Metric | INDVIndivior Pharmace… | AVPTAvePoint, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | — | +8.0% |
| ROA (TTM)Return on assets | +19.1% | +4.9% |
| ROICReturn on invested capital | +3.4% | +11.4% |
| ROCEReturn on capital employed | +79.1% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | $156M | -$471M |
| Cash & Equiv.Liquid assets | $195M | $481M |
| Total DebtShort + long-term debt | $351M | $10M |
| Interest CoverageEBIT ÷ Interest expense | 10.88x | 130.95x |
AVPT leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
INDV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INDV five years ago would be worth $38,493 today (with dividends reinvested), compared to $10,108 for AVPT. Over the past 12 months, INDV leads with a +247.1% total return vs AVPT's -39.5%. The 3-year compound annual growth rate (CAGR) favors AVPT at 32.3% vs INDV's 26.4% — a key indicator of consistent wealth creation.
| Metric | INDVIndivior Pharmace… | AVPTAvePoint, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +13.7% | -22.3% |
| 1-Year ReturnPast 12 months | +247.1% | -39.5% |
| 3-Year ReturnCumulative with dividends | +102.0% | +131.8% |
| 5-Year ReturnCumulative with dividends | +284.9% | +1.1% |
| 10-Year ReturnCumulative with dividends | +291.3% | +5.0% |
| CAGR (3Y)Annualised 3-year return | +26.4% | +32.3% |
INDV leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
INDV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INDV is the less volatile stock with a 0.68 beta — it tends to amplify market swings less than AVPT's 1.06 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INDV currently trades 99.5% from its 52-week high vs AVPT's 50.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INDVIndivior Pharmace… | AVPTAvePoint, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 1.06x |
| 52-Week HighHighest price in past year | $40.81 | $20.25 |
| 52-Week LowLowest price in past year | $10.63 | $8.83 |
| % of 52W HighCurrent price vs 52-week peak | +99.5% | +50.7% |
| RSI (14)Momentum oscillator 0–100 | 77.6 | 60.0 |
| Avg Volume (50D)Average daily shares traded | 2.7M | 1.5M |
INDV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates INDV as "Buy" and AVPT as "Buy". Consensus price targets imply 70.4% upside for AVPT (target: $18) vs 10.0% for INDV (target: $45).
| Metric | INDVIndivior Pharmace… | AVPTAvePoint, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $44.67 | $17.50 |
| # AnalystsCovering analysts | 3 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | +2.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
INDV leads in 3 of 6 categories (Valuation Metrics, Total Returns). AVPT leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallIndivior Pharmaceuticals Inc (INDV)Leads 3 of 6 categories
Loading custom metrics...
INDV vs AVPT: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is INDV or AVPT a better buy right now?
For growth investors, AvePoint, Inc.
(AVPT) is the stronger pick with 26. 9% revenue growth year-over-year, versus 4. 3% for Indivior Pharmaceuticals Inc (INDV). Indivior Pharmaceuticals Inc (INDV) offers the better valuation at 24. 8x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Indivior Pharmaceuticals Inc (INDV) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INDV or AVPT?
On trailing P/E, Indivior Pharmaceuticals Inc (INDV) is the cheapest at 24.
8x versus AvePoint, Inc. at 68. 5x. On forward P/E, Indivior Pharmaceuticals Inc is actually cheaper at 13. 0x.
03Which is the better long-term investment — INDV or AVPT?
Over the past 5 years, Indivior Pharmaceuticals Inc (INDV) delivered a total return of +284.
9%, compared to +1. 1% for AvePoint, Inc. (AVPT). Over 10 years, the gap is even starker: INDV returned +291. 3% versus AVPT's +5. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INDV or AVPT?
By beta (market sensitivity over 5 years), Indivior Pharmaceuticals Inc (INDV) is the lower-risk stock at 0.
68β versus AvePoint, Inc. 's 1. 06β — meaning AVPT is approximately 57% more volatile than INDV relative to the S&P 500.
05Which is growing faster — INDV or AVPT?
By revenue growth (latest reported year), AvePoint, Inc.
(AVPT) is pulling ahead at 26. 9% versus 4. 3% for Indivior Pharmaceuticals Inc (INDV). On earnings-per-share growth, the picture is similar: Indivior Pharmaceuticals Inc grew EPS 108. 3% year-over-year, compared to 193. 8% for AvePoint, Inc.. Over a 3-year CAGR, AVPT leads at 21. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INDV or AVPT?
Indivior Pharmaceuticals Inc (INDV) is the more profitable company, earning 16.
9% net margin versus 8. 4% for AvePoint, Inc. — meaning it keeps 16. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INDV leads at 21. 4% versus 7. 9% for AVPT. At the gross margin level — before operating expenses — INDV leads at 80. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INDV or AVPT more undervalued right now?
On forward earnings alone, Indivior Pharmaceuticals Inc (INDV) trades at 13.
0x forward P/E versus 27. 6x for AvePoint, Inc. — 14. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVPT: 70. 4% to $17. 50.
08Which pays a better dividend — INDV or AVPT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is INDV or AVPT better for a retirement portfolio?
For long-horizon retirement investors, Indivior Pharmaceuticals Inc (INDV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
68), +291. 3% 10Y return). Both have compounded well over 10 years (INDV: +291. 3%, AVPT: +5. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INDV and AVPT?
These companies operate in different sectors (INDV (Healthcare) and AVPT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: INDV is a small-cap quality compounder stock; AVPT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(INDV: 19.2% · AVPT: 28.6%)Net Margin>
%
(INDV: 19.4% · AVPT: 8.3%)P/E Ratio<
x
(INDV: 24.8x · AVPT: 68.5x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.